英夫利西单抗联合草酸艾司西酞普兰治疗抑郁症合并类风湿关节炎患者的临床疗效

doi:10.3969/j.issn.1671-7171.2025.03.013

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1203 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the clinical efficacy of infliximab combined with escitalopram oxalate in the treatment of patients with depression and rheumatoid arthritis. 【Methods】A total of 180 patients with depression combined with rheumatoid arthritis admitted to Wuxi Mental Health Center from January 2018 to March 2022 were selected and divided into the control group and the observation group according to random number table method, with 90 cases in each group. The control group was treated with escitalopram oxalate tablets on the basis of basic treatment; The observation group was additionally treated with infliximab for 30 weeks. The clinical efficacy, occurrence of adverse reactions, pain score, depression score, erythrocyte subsidence rate (ESR), tumor necrosis factor-α (TNF-α), C-reactive protein (CRP), rheumatoid factor (RF), homocysteine (Hcy), brain-derived neurotrophic factor (BDNF), 5-hydroxytryptophan (5-HT) and dopamine were compared between the two groups cortisol levels.【Results】 6 cases fell off in the observation group, and 84 cases were included in the analysis. In the control group, 4 cases fell off, and 86 cases were included in the analysis. After treatment, the total effective rate of the observation group was 88.10%, which was significantly higher than that of the control group (72.09%), and the difference was statistically significant (P<0.05). After treatment, the pain score, depression score, ESR, TNF-α, CRP, RF, Hcy and cortisol levels in the observation group were lower than those in the control group, while the levels of BDNF, 5-HT and dopamine were higher than those in the control group, with statistical significance (P<0.05). There was no significant difference in the incidence of adverse drug reactions between the two groups (P>0.05). 【Conclusion】Infliximab combined with escitalopram oxalate in the treatment of patients with depression and rheumatoid arthritis can reduce joint inflammation and improve the effect of anti-depression.

Key words： Depressive Disorder Arthritis, Rheumatoid Antibodies, Monoclonal Citalopram Treatment Outcome

Received: 26 September 2024

PACS:

R749.42

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIN Yuanyuan
	SHAO Tihong

Cite this article:

LIN Yuanyuan,SHAO Tihong. Clinical Efficacy of Infliximab Combined with Escitalopram Oxalate in the Treatment of Patients with Depression and Rheumatoid Arthritis[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(3): 412-415.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.03.013 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I3/412

[1] SMOLEN J S, LANDEWE R, BERGSTRA S A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update[J].Ann Rheum Dis,2023,82(1):3-18.
[2] DIEP L, BARBIER V, DOUSSIERE M, et al. Comparison of rheumatoid arthritis patients' 2-year infliximab, abatacept, and tocilizumab persistence rates[J].J Clin Med,2022,11(20):5978.
[3] LEONE G M, MANGANO K, PETRALIA M C, et al. Past, present and (foreseeable) future of biological anti-TNF alpha therapy[J].J Clin Med,2023,12(4):1630.
[4] 吴世鹏,周文芝,赵得晟,等. 阿立哌唑联合草酸艾司西酞普兰治疗精神分裂症合并抑郁焦虑的疗效及对血清因子的影响[J].中南医学科学杂志,2021,49(2):219-222.
[5] ALETAHA D, NEOGI T, SILMAN A J, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative[J].Arthritis Rheum,2010,62(9):2569-2581.
[6] HAMILTON M. A rating scale for depression[J].J Neurol Neurosurg Psychiatry,1960,23(1):56-62.
[7] 张子云,汪晖,王霞,等. 湖北省类风湿关节炎病人焦虑、抑郁状况及其危险因素[J].护理研究,2021,35(19):3550-3555.
[8] JONES A E, ANWAR S, KAVANOOR S K, et al. Correlation of depression and anxiety with rheumatoid arthritis[J].Cureus,2022,14(3):e23137.
[9] 汪雪,武平,罗云,等. 艾灸治疗类风湿关节炎及对相关负性情绪的影响[J].中国针灸,2022,42(11):1221-1225.
[10] 武小玲,王森岩,赵思俊,等. 选择性5-羟色胺再摄取抑制剂联合用药治疗难治性抑郁症研究进展[J].中国药理学与毒理学杂志,2022,36(10):776-783.
[11] 吴佩怡. 基于脑皮层形态结构的重性抑郁障碍发病及SSRI疗效研究[D]. 山西:山西医科大学,2022.
[12] FAKRA E, MAROTTE H. Rheumatoid arthritis and depression[J].Joint Bone Spine,2021,88(5):105200.
[13] HANRAHAN C, LEE T. Network meta-analysis of infliximab biosimilars for the treatment of rheumatoid arthritis[J].Am J Health Syst Pharm,2021,78(8):697-704.
[14] 严美茹,张燕平,罗瑞琦,等. 英夫利西单抗通过c-Jun N末端激酶通路减轻脑出血小鼠的炎症损伤[J].中国临床药理学杂志,2023,39(8):1099-1103.
[15] 徐丽娟,李海燕,田军彪,等. 益智解郁汤联合草酸艾司西酞普兰对脑卒中后抑郁的疗效观察[J].中华中医药杂志,2021,36(4):2419-2422.
[16] 曹静,李娟. 不同剂量艾司西酞普兰治疗广泛性焦虑患者的疗效及对5-HT、GABA含量的影响[J].医学临床研究,2023,40(9):1303-1306.